LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors

Sai Duriseti; James A. Kavanaugh; Jeff Szymanski; Yi Huang; Franco Basarabescu; Aadel Chaudhuri; Lauren Henke; Pamela Samson; Alexander Lin; Clifford Robinson; Matthew B. Spraker

doi:10.1016/j.radonc.2021.11.023

journal article Feb 01, 2022

LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors

Sai Duriseti James A. Kavanaugh Jeff Szymanski Yi Huang

Franco Basarabescu Aadel Chaudhuri Lauren Henke Pamela Samson Alexander Lin Clifford Robinson Matthew B. Spraker

Radiotherapy and Oncology Vol. 167 pp. 317-322 · Elsevier BV

View at Publisher Save 10.1016/j.radonc.2021.11.023

Topics

No keywords indexed for this article. Browse by subject →

References

22

[1]

Spencer "Palliative radiotherapy" BMJ (2018)

[2]

Shiue "Histology, tumor volume, and radiation dose predict outcomes in NSCLC patients after stereotactic ablative radiotherapy" J Thorac Oncol (2018) 10.1016/j.jtho.2018.06.007

[3]

Nguyen "Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial" JAMA Oncol (2019) 10.1001/jamaoncol.2019.0192

[4]

Ricco "Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry’s experience" Radiat Oncol (2017) 10.1186/s13014-017-0773-4

[5]

Allibhai "The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer" Int J Radiat Oncol (2013) 10.1016/j.ijrobp.2013.08.020

[6]

Peterson "Stereotactic body radiotherapy for large (> 5 cm) non–small-cell lung cancer" Clin Lung Cancer (2017) 10.1016/j.cllc.2016.11.020

[7]

Woody "Stereotactic body radiation therapy for non-small cell lung cancer tumors greater than 5 cm: safety and efficacy" Int J Radiat Oncol (2015) 10.1016/j.ijrobp.2015.01.045

[8]

Verma "Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non–small cell lung tumors" Cancer (2017) 10.1002/cncr.30375

[9]

Videtic "Stereotactic body radiation therapy for early-stage non-small cell lung cancer: executive summary of an ASTRO evidence-based guideline" Pract Radiat Oncol (2017) 10.1016/j.prro.2017.04.014

[10]

Billena "A current review of spatial fractionation: back to the future?" Int J Radiat Oncol Biol Phys (2019) 10.1016/j.ijrobp.2019.01.073

[11]

The Technical and Clinical Implementation of LATTICE Radiation Therapy (LRT)

Xiaodong Wu, Naipy C. Perez, Yi Zheng et al.

Radiation Research 2020 10.1667/rade-20-00066.1

[12]

Huhn "Spatially fractionated GRID radiation treatment of advanced neck disease associated with head and neck cancer" Technol Cancer Res Treat (2006) 10.1177/153303460600500608

[13]

Mohiuddin "Spatially Fractionated Grid Radiation (SFGRT): a novel approach in the management of recurrent and unresectable soft tissue sarcoma" Int J Radiat Oncol Biol Phys (2009) 10.1016/j.ijrobp.2009.07.1200

[14]

Blanco Suarez JM, Amendola BE, Perez N, Amendola M, Wu X. The use of Lattice Radiation Therapy (LRT) in the treatment of bulky tumors: a case report of a large metastatic mixed Mullerian Ovarian Tumor. Cureus. 7(11). doi:10.7759/cureus.389. 10.7759/cureus.389

[15]

Amendola BE, Perez NC, Wu X, Amendola MA, Qureshi IZ. Safety and efficacy of lattice radiotherapy in voluminous non-small cell lung cancer. Cureus. 11(3). doi:10.7759/cureus.4263 10.7759/cureus.4263

[16]

Duriseti "Spatially fractionated stereotactic body radiotherapy (Lattice SBRT) for large tumors" Adv Radiat Oncol (2021) 10.1016/j.adro.2020.100639

[17]

Benedict "Stereotactic body radiation therapy: the report of AAPM Task Group 101: stereotactic body radiation therapy: the report of TG101" Med Phys (2010) 10.1118/1.3438081

[18]

PROMIS. Accessed December 26, 2020. https://www.healthmeasures.net/explore-measurement-systems/promis.

[19]

Dueck "Assessment of adverse events from the patient perspective in a phase 3 metastatic castration-resistant prostate cancer clinical trial" JAMA Oncol (2020) 10.1001/jamaoncol.2019.3332

[20]

Basch "Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)" Clin Trials (2021) 10.1177/1740774520975120

[21]

Jensen "United States population-based estimates of patient-reported outcomes measurement information system symptom and functional status reference values for individuals with cancer" J Clin Oncol (2017) 10.1200/jco.2016.71.4410

[22]

Shaverdian "Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors" Ann Oncol (2020) 10.1016/j.annonc.2020.09.016

Cited By

55

Nibbling toward optimal sphere packing for lattice spatially fractionated radiotherapy of large and bulky unresectable tumors

Joshua Misa, James R. Castle · 2025

Medical Physics

Impressive Results after “Metabolism-Guided” Lattice Irradiation in Patients Submitted to Palliative Radiation Therapy: Preliminary Results of LATTICE_01 Multicenter Study

Gianluca Ferini, Silvana Parisi · 2022

Cancers

Metrics

55

Citations

22

References

Details

Published: Feb 01, 2022
Vol/Issue: 167
Pages: 317-322
License: View

Authors

Department of Microbiology, The University of Hong Kong, Hong Kong, China

Department of Radiation Oncology Hospital of the University of Pennsylvania Philadelphia Pennsylvania

Cite This Article

Sai Duriseti, James A. Kavanaugh, Jeff Szymanski, et al. (2022). LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors. Radiotherapy and Oncology, 167, 317-322. https://doi.org/10.1016/j.radonc.2021.11.023

LITE SABR M1: A phase I trial of Lattice stereotactic body radiotherapy for large tumors

You May Also Like